KDR and neoplasm: Anti-vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) can modulate the tumor immune microenvironment, supporting the theoretical basis for combining anti-VEGFR-TKIs and ICIs in mCRC.